Search Results - "JOYEUX, I"

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients by TARTOUR, E, DORVAL, T, MOSSERI, V, DENEUX, L, MATHIOT, C, BRAILLY, H, MONTERO, F, JOYEUX, I, POUILLART, P, FRIDMAN, W. H

“…Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6…”
Get full text

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings by TARTOUR, E, MEHTALI, M, HERRMANN, R, POUILLART, P, FRIDMAN, W. H, DORVAL, T, SASTRE-GARAU, X, JOYEUX, I, MATHIOT, C, PLEAU, J. M, SQUIBAN, P, ROCHLITZ, C, COURTNEY, M, JANTSCHEFF, P

“…Various studies have emphasized an immunodepression state observed at the tumour site. To reverse this defect and based upon animal studies, we initiated a…”
Get full text

Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family by MONTERO-JULIAN, F. A, BRAILLY, H, FRIDMAN, W. H, TARTOUR, E, SAUTES, C, JOYEUX, I, DORVAL, T, MOSSERI, V, YASUKAWA, K, WIJDENES, J, ADLER, A, GORIN, I

“…gp130 acts as a common transducing signal chain for all receptors belonging to the interleukin (IL)-6 receptor family. The IL-6-related cytokines [IL-6, IL-11,…”
Get full text

Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice by TARTOUR, E, FOSSIEZ, F, BANCHEREAU, J, FRIDMAN, W. H, WIJDENES, J, LEBECQUE, S, SAUTES-FRIDMAN, C, JOYEUX, I, GALINHA, A, GEY, A, CLARET, E, SASTRE-GARAU, X, COUTURIER, J, MOSSERI, V, VIVES, V

“…Interleukin (IL) 17 is a proinflammatory cytokine secreted mainly by activated human memory CD4 T cells that induces IL-6, IL-8, and nitric oxide. Because IL-6…”
Get full text

Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with renal cell carcinoma by Thiounn, N, Mathiot, C, Tartour, E, Joyeux, I, Peyret, C, Brandely, M, Deslignieres, S, Debré, B, Fridman, W H

“…Twenty renal cell carcinomas were cultured in the presence of 200 IU/ml of recombinant interleukin-2; tumour-infiltrating lymphocytes (TIL) developed in 70% of…”
Get more information

Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B‐fragment of Shiga toxin by Lee, Ren‐Shiang, Tartour, Eric, Van der Bruggen, Pierre, Vantomme, Valérie, Joyeux, Isabelle, Goud, Bruno, Fridman, Wolf Herman, Johannes, Ludger

“…Targeting exogenous antigen into the MHC class I‐restricted presentation pathway is a prerequisite for the induction of cytotoxic T lymphocytes (CTL) which…”
Get full text

Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function by Tartour, E, Latour, S, Mathiot, C, Thiounn, N, Mosseri, V, Joyeux, I, D'Enghien, C D, Lee, R, Debre, B, Fridman, W H

“…It has been reported that in mice and in humans, tumor-infiltrating lymphocytes (TIL) may exhibit a defect in CD3-zeta-chain expression. Therefore, the level…”
Get more information

Non-cytotoxic CD4 tumourinfiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2 by Mathiot, C., Thiounn, N., Tartour, E., Flam, T., Peyret, C., Joyeux, I., Zerbib, M., Brandely, M., Debré, B., Fridman, W.H.

Get full text

Non-cytotoxic CD4 tumour-infiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2 by Mathiot, C, Thiounn, N, Tartour, E, Flam, T, Peyret, C, Joyeux, I, Zerbib, M, Brandely, M, Debré, B, Fridman, W H

Get full text

CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study by Thiounn, N, Mathiot, C, Flam, T, Tartour, E, Peyret, C, Joyeux, I, Abecassis, J P, Zerbib, M, Fridman, W H, Debré, B

“…This study analyzed clinical response induced by TIL in patients with renal cell carcinoma previously treated by interleukin-2. Six patients (4 men, 2 women,…”
Get more information